Sign in

CIK 0001601830

  • Large accelerated filer

RECURSION PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RXRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464099738
Phone
+1 385-269-0203
Business address
41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
Former names
Recursion Pharmaceuticals, LLC
  1. 4 Shares withheld for taxes Chief Financial Officer gave up 11,962 shares (to pay taxes)
  2. 4 Planned sale Chief Financial Officer sold 30,000 shares at an average $6.35 ($190,434)
  3. 4 Planned sale Chief Executive Officer sold 50,000 shares at an average $6.86 ($343,000)
  4. 4 Planned sale Director sold 11,447 shares at $6.82 ($78,083)
  5. 4 Grant or award Chief R&D Commercial Officer acquired 496,972 shares (grant or award)
  6. 4 Planned sale President and COO sold 6,000 shares at $8.13 ($48,809)
  7. 4 Planned sale Director sold 11,447 shares at $8.48 ($97,041)
  8. 4 Planned sale Chief Executive Officer sold 100,000 shares at an average $7.48 ($747,500)
  9. 4/A Conversion Chief Executive Officer acquired 100,000 shares (conversion)
  10. 4 Planned sale Chief Financial Officer sold 30,000 shares at an average $7.28 ($218,354)
  11. 4 Planned sale Director sold 11,447 shares at $7.32 ($83,735)
  12. 4 Grant or award Director acquired 1,592 shares (grant or award)
  13. 4 Grant or award Director acquired 1,843 shares (grant or award)
  14. 4 Grant or award Director acquired 1,843 shares (grant or award)
  15. 4 Grant or award Director acquired 1,441 shares (grant or award)
  16. 4 Planned sale President and COO sold 6,000 shares at $7.22 ($43,290)
  17. 4 Planned sale Director sold 11,447 shares at $9.51 ($108,806)
  18. 4 Planned sale Chief Financial Officer sold 30,000 shares at an average $9.30 ($278,880)
  19. 4 Planned sale Director sold 11,447 shares at $8.45 ($96,763)
  20. 4 Planned sale Chief Executive Officer sold 100,000 shares at an average $8.71 ($871,000)

Page 9 of 26 · 512 filings